Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Immuno-Oncology (IO) therapies have revolutionized cancer therapy and are becoming the
standard of care for many cancers. Monitoring how well IO therapies work against cancer is
difficult due to the complexity of the immune system and the fact that an immune response may
initially increase, rather than decrease, the size of a tumor. An early response marker would
be beneficial to determine which patients should remain on a given treatment or combination
of treatments, and which patients should seek other treatment options. 18F-LY3546117 is a
radiolabeled tracer that binds to a specific protein (Granzyme B) that is found in the human
immune system and is thought to trigger programmed cell death. It is thought that imaging
Granzyme B activity in tumors and elsewhere in the body using a Positron Emission Tomography
(PET) scan will allow doctors to monitor the progress of IO therapy.